TCGA

Tempus Contributes De-Identified Cancer Data to Planned Data Enclave

Retrieved on: 
Thursday, March 14, 2024
Technology, Research, Software, Health, General Health, Data Management, Science, Artificial Intelligence, Oncology, Health informatics, NCI, Informatics, TCGA, Learning, Associate, Intelligence, Patient, API, Knowledge, National Cancer Institute, Information technology, Cancer, Doctor of Philosophy, MD, NIH, Medicine, Neoplasm, Bangladesh Technical Education Board, Data, The Cancer Genome Atlas, Medical imaging

This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer.

Key Points: 
  • This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer.
  • These de-identified data files with associated limited clinical information are derived from advanced-stage cancer patients sequenced with Tempus’ signature xT assay.
  • All summary level results returned to the users by the NCI Data Enclave will be openly accessible to the full cancer research community.
  • “This data will greatly expand the genomic data resources available to the cancer research community.

Mount Sinai Researchers Find More Than 4,700 Gene Clusters Crucial for Prognosis in 32 Cancer Types

Retrieved on: 
Monday, November 13, 2023
Doctor of Philosophy, Research, Cancer, Genome Research, TCGA, Human Genome Sciences, The Cancer Genome Atlas, Vaccine, Genetics

NEW YORK, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed "prognostic modules," that significantly influence the progression of 32 different types of cancer.

Key Points: 
  • NEW YORK, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed "prognostic modules," that significantly influence the progression of 32 different types of cancer.
  • Previous research often focused on isolated gene functions in specific cancer types.
  • We have identified 4,749 distinct co-regulated gene modules that play a pivotal role in cancer progression," explained Dr. Zhang.
  • "Our findings offer fertile ground for the next wave of cancer research and treatment strategies," said Dr. Zhang.

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023

Retrieved on: 
Friday, November 3, 2023
TCGA, TCE, CD3, QSP, SITC, Immunotherapy, Fragment crystallizable region, Database, Immunohistochemistry, Epithelium, Messenger, Annual general meeting, Society, Patient, Vaccine, Medical imaging

ZÜRICH, Switzerland, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-kind, antibody-based, bivalent & bispecific MAGE-A4 T-cell engager (TCE) targeting MAGE-A4, an intracellular cancer protein with expression in several frequent and difficult to treat solid tumors, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Key Points: 
  • The demonstration of high MAGE-A4 protein expression in SQ-NSCLC and potent preclinical cytotoxicity of CDR404, highlights the therapeutic promise of CDR404 in HLA-A*02:01+ patients with SQ-NSCLC.
  • “These milestones underscore the continued advancement of CDR404’s potential as an off-the-shelf precision immunotherapy for MAGE-A4+ solid tumors.
  • Treatment with four different doses of CDR404 induced complete tumor regression in the in vivo SQ-NSCLC NCI-H1703 xenograft model.
  • The QSP model predicted doses of CDR404 which might have the most favorable benefit-risk profile for patients in the Phase 1 trial.

AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023

Retrieved on: 
Wednesday, November 1, 2023
TKI, TILS, Patient, Neoplasm, The Cancer Genome Atlas, TCGA, NSCLC, PTEN, Progression-free survival, Biomarker, Therapy, Booth, ICI, BRCA1, Data, PFS, PIK3CA, Phenotype, Inflammation, TIL, Samsung Medical Center, BRCA2, OR, TNBC, IL1A, SITC, Immunotherapy, Methylation, ITIL, Annual general meeting, Breast cancer, Triple-negative breast cancer, Gene, Tumor microenvironment, Lung cancer, Society, IL17A, Cancer, TFI, TME, STIL, Mutation, EGFR, Medical imaging

The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.

Key Points: 
  • The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.
  • Patients with an inflamed immune phenotype after EGFR-TKI treatment showed a more favorable response to subsequent immune checkpoint inhibitors (ICI) treatment.
  • Another study investigated the effect of tumor fragmentation index (TFI), the number of tumor fragments per total tumor area, in TME.
  • Visit Lunit's booth at SITC 2023 at Booth #227 to learn more about these pioneering studies.

CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Bispecific monoclonal antibody, The Cancer Genome Atlas, Adenocarcinoma, TCGA, TCE, NSCLC, ESMO, IHC, HPV, Data, Head, Bladder cancer, Neck, Neoplasm, Histology, Messenger, Bivalent, Patient, HLA, Vaccine

ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispecific and bivalent antibody fragment-based T-cell engager (TCE) targeting MAGE-A4, an intracellular protein which is presented on HLA-A*02:01 on the surface of cancer cells, at the ESMO Congress 2023, occurring October 20-24 in Madrid, Spain.

Key Points: 
  • The key objective of this study was for CDR-Life to explore MAGE-A4 expression levels in solid tumors using The Cancer Genome Atlas (TCGA) mRNA dataset.
  • In addition, subgroups of high MAGE-A4 expression were present across a wide range of solid cancers including lung adenocarcinoma, ovarian and gastric cancers.
  • “CDR404 is a novel, bispecific and bivalent T-cell engager differentiated from previous solid tumor T-cell engagers targeting MAGE-A4 in the clinic.
  • The MAGE-A4 mRNA distribution profiles across multiple tumor types indicate, that a tumor MAGE-A4 assay will be indispensable for trial screening.

BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform

Retrieved on: 
Thursday, October 5, 2023
Algorithm, Partnership, American Cancer Society, Machine learning, JCVI, Anomaly, J. Craig Venter Institute, Data, The Cancer Genome Atlas, Cancer, Artificial intelligence, Bullfrog, Colorectal cancer, TCGA, Literature, Neoplasm, Woman, Genomics, Research, Skin, Vaccine

GAITHERSBURG, Md., Oct. 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that it has identified multiple potential therapeutic targets, including three novel targets, for colorectal cancer using the Company’s proprietary AI-driven platform, bfLEAP™. The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a world-leading genomics research and innovation institution. JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.

Key Points: 
  • The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a world-leading genomics research and innovation institution.
  • JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.
  • “TCGA has been extensively analyzed by scientists for more than a decade, yet in a matter of weeks, we were able to identify multiple new drug target candidates with previously undocumented potential in colorectal cancer from this same dataset,” stated Vin Singh, Chairman and CEO of BullFrog AI.
  • "These findings demonstrate the power and potential of our bfLEAP™ platform, which combines advanced AI algorithms with rich biological data to identify novel targets for a wide range of diseases.

iSpecimen Launches New Virtual Cancer Sequencing Procurement Program

Retrieved on: 
Wednesday, August 30, 2023
NRAS, Tissue, KRAS, National Human Genome Research Institute, TP53, Serum, Breast, Cancer, National Cancer Institute, Brain, Prostate, Lung, Colon, Plasma, The Cancer Genome Atlas, PTEN, EGFR, Risk, Melanoma, DTC, MET, TCGA, RET, ALK, Medical imaging

LEXINGTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the launch of a new program that gives researchers consistent and direct access to mutation-characterized formalin-fixed, paraffin-embedded (“FFPE”) cancer tumor tissues, relieving a major bottleneck in cancer research. The program will initially offer samples for lung, colon and breast cancers.

Key Points: 
  • The genetic signatures of cancer tumor tissues provide important information necessary to develop new treatments and diagnostics.
  • “This is a very important program for the future of iSpecimen.
  • Our new cancer sequencing procurement program provides cancer researchers with access to mutation-characterized FFPE tumor tissues without requiring that they manage the risk and resource-intense course of overseeing the sequencing process,” said Tracy Curley, iSpecimen’s CEO.
  • As this program progresses, pre-screened samples will be offered for a number of additional cancer types, including pancreatic, renal, brain, ovarian, gastric, melanoma, bladder and prostate.

Roswell Park Study May Provide Clues to Treating Colorectal Cancer More Effectively in Younger Patients

Retrieved on: 
Sunday, June 4, 2023
Roswell Park Comprehensive Cancer Center, American Society of Clinical Oncology, The James Cancer Hospital, Doctor of Philosophy, Oncogene, Incidence, DO, Metabolism, Patient, The Cancer Genome Atlas, Risk, Informatics, Colorectal cancer, Body mass index, H. Lee Moffitt Cancer Center & Research Institute, TCGA, PSA, Prostate cancer, MYC, University, National Cancer Institute, AYA, Research, MS, Cancer, Diagnosis, Growth, BMI, Smoking, PD-L1, Metastasis, Behavior, NRAS, University of Oklahoma Health Sciences Center, Lipid, Cell, Dicarboxylic acid, Ohio State University, CRC, Health informatics, ASCO, Kynurenine, CDT, Gene, Society, Pharmaceutical industry, Birth control, Medical imaging, Upstate New York, MD, Roswell Park

That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.

Key Points: 
  • That information could guide the development of new treatments for younger patients, who typically have poorer outcomes.
  • The team hopes the results of their study will help future studies zero in on new ways of treating colorectal cancer in younger patients.
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

Lunit Demonstrates Predictive Value of AI-Biomarker Platform at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Abstract, Therapy, ICI, TIL, The Cancer Genome Atlas, TAA, Neoplasm, MSS, American Society of Clinical Oncology, Clinical trial, Pathology, Booth, Cancer, Lung cancer, Head, Research, NSCLC, Cell, Immunotherapy, PCR, ASCO, Publication, LARC, Collection, Patient, Data, AUC, TME, Annual general meeting, HNSCC, MET, Poster, Chemoradiotherapy, CRT, Tumor microenvironment, Society, TCGA, Neoadjuvant therapy, NCCE, Medical imaging

SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global leader of AI-powered cancer diagnostics and therapeutics solutions, is set to make a significant impact at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. This year, Lunit will present 16 abstracts at the conference, showcasing the groundbreaking capabilities of its AI-biomarker platform, Lunit SCOPE. This comprehensive collection of studies includes 10 poster presentations and 6 online publications, covering a wide spectrum of topics. From predicting clinical outcomes to exploring the complex dynamics of tumor microenvironments, these advancements highlight Lunit's unwavering commitment to advancing AI pathology research and personalized cancer care.

Key Points: 
  • This year, Lunit will present 16 abstracts at the conference, showcasing the groundbreaking capabilities of its AI-biomarker platform, Lunit SCOPE.
  • This comprehensive collection of studies includes 10 poster presentations and 6 online publications, covering a wide spectrum of topics.
  • "I am excited to present the groundbreaking results from our studies at ASCO, showcasing the immense impact of the Lunit SCOPE suite," said Brandon Suh, CEO of Lunit.
  • "Through our AI-biomarker platform, we are paving the way to provide valuable insights into cancer progression, immune responses, and treatment efficacy.

Wistar Scientists Discover Innate Tumor Suppression Mechanism

Retrieved on: 
Thursday, May 4, 2023
Online, Perelman School of Medicine at the University of Pennsylvania, Database, CRISPR, Human, Cell biology, Ashkenazi Jews, University, Molecule, Life, Fox Chase Cancer Center, University of Kansas, Culture, Neoplasm, Infection, St. Jude Children's Research Hospital, Cancer, American Association for Cancer Research, Biomedical Research, Mutation, Research, Immunotherapy, Ellen, PADI4, Citrulline, Patient, Wistar Institute, Risk, Machine learning, Engineering, Immune system, Ausländer, Paper, Mouse, Artificial intelligence, Gene, TCGA, NIH, African Americans, Genome, Vaccine, Pharmaceutical industry, Medical device, Wistar, Cancer Discovery (journal)

Now, in a recent study published in Cancer Discovery , a journal of the American Association for Cancer Research, researchers at The Wistar Institute have uncovered a key mechanism as to how p53 suppresses tumors.

Key Points: 
  • Now, in a recent study published in Cancer Discovery , a journal of the American Association for Cancer Research, researchers at The Wistar Institute have uncovered a key mechanism as to how p53 suppresses tumors.
  • Publication information: An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression, Cancer Discovery, 2023.
  • Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology.
  • Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside.